The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat

被引:69
作者
Natesan, Sridhar
Svensson, Kjell A.
Reckless, Greg E.
Nobrega, Jose N.
Barlow, Karen B. L.
Johansson, Anette M.
Kapur, Shitij
机构
[1] Ctr Addict & Mental Hlth, Schizophrenia Program, Toronto, ON M5S 2S1, Canada
[2] Ctr Addict & Mental Hlth, PET Ctr, Toronto, ON M5S 2S1, Canada
[3] Ctr Addict & Mental Hlth, Neuroimaging Res Sect, Toronto, ON M5S 2S1, Canada
[4] Lilly Res Labs, Indianapolis, IN USA
[5] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
D O I
10.1124/jpet.106.102905
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dopamine stabilizers are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl- phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D-2 receptor [(-)-OSU6162, K-i = 447 nM; ACR16, K-i > 1 mu M], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D-2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose- dependent striatal D-2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalepsy, but it failed to activate habituated animals. In the conditioned avoidance response assay, ACR16 was clearly more efficacious than (-)OSU6162. In addition, both these compounds demonstrated significant preferential Fos induction in the nucleus accumbens compared with the dorsolateral striatum, a strong predictor of atypical antipsychotic efficacy. The results suggest that dopamine stabilizers exhibit locomotor stabilizing as well as antipsychoticlike effects, with low motor side effect liability, in a dose range that corresponds to high D-2 in vivo occupancy.
引用
收藏
页码:810 / 818
页数:9
相关论文
共 40 条
[1]   Do we still believe in the dopamine hypothesis? New data bring new evidence [J].
Abi-Dargham, A .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 :S1-S5
[2]   Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia [J].
Abi-Dargham, A ;
Moore, H .
NEUROSCIENTIST, 2003, 9 (05) :404-416
[3]   DOPAMINE AND BASAL GANGLIA DISEASES [J].
BARBEAU, A .
ARCHIVES OF NEUROLOGY, 1961, 4 (01) :97-&
[4]   The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys [J].
Brandt-Christensen, M ;
Andersen, MB ;
Fink-Jensen, A ;
Werge, T ;
Gerlach, J .
JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (01) :11-19
[5]  
Carlsson Arvid, 2006, Dialogues Clin Neurosci, V8, P137
[6]   Schizophrenia: From dopamine to glutamate and back [J].
Carlsson, ML ;
Carlsson, A ;
Nilsson, M .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (03) :267-277
[7]  
Carlsson ML, 2002, EUR NEUROPSYCHOPHARM, V12, pS167
[8]   REGIONALLY SPECIFIC EFFECTS OF ATYPICAL ANTIPSYCHOTIC-DRUGS ON STRIATAL FOS EXPRESSION - THE NUCLEUS-ACCUMBENS SHELL AS A LOCUS OF ANTIPSYCHOTIC ACTION [J].
DEUTCH, AY ;
LEE, MC ;
IADAROLA, MJ .
MOLECULAR AND CELLULAR NEUROSCIENCE, 1992, 3 (04) :332-341
[9]   Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains [J].
Ekesbo, A ;
Torstenson, R ;
Hartvig, P ;
Carlsson, A ;
Sonesson, C ;
Waters, N ;
Tedroff, J ;
Långström, B .
NEUROPHARMACOLOGY, 1999, 38 (03) :331-338
[10]   (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease [J].
Ekesbo, A ;
Andren, PE ;
Gunne, LM ;
Tedroff, J .
NEUROREPORT, 1997, 8 (11) :2567-2570